This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie policy for more information on the cookies we use and how to delete or block them.

 Ok, Got It

Join PI and the Victorian Government in piloting the FebriDx® test to help triage patients with symptoms of respiratory tract infection

We are seeking GPs and other healthcare professionals in Victoria, Australia to pilot a new point-of-care test to help differentiate patients with viral from bacterial acute respiratory tract infections.

FebriDx® is a simple 10-minute point-of-care fingerstick test that helps differentiate viral infections that may necessitate isolation, from bacterial infections that require antibiotic therapy.

Due to the COVID-19 pandemic and potential impact of the impending flu season, Lumos Diagnostics, a Planet Innovation company, is working with the Victorian Government to demonstrate the benefits and impact that the FebriDx test may deliver as an acute respiratory infection (ARI) patient triage tool in the Australian healthcare system.

The FebriDx test is CE-marked and included on the ARTG (Australian Register of Therapeutic Goods). It is commercially available in Europe, Canada, Australia and various other countries.

We are asking for GPs, emergency departments and other healthcare professionals in the state of Victoria to help improve patient triaging by participating in this free FebriDx initiative. Please register to express your interest in participating, or to receive more information.

FebriDx Trial

Healthcare professionals: Register your interest

MORE INFORMATION

About FebriDx

FebriDx is a 10-minute point-of-care (POC) test that rapidly assesses the body’s host immune response to an acute respiratory infection (ARI) and helps identify viral infections that may necessitate isolation from bacterial infections that require antibiotic therapy.

By enabling a rapid diagnostic triage at the initial visit or screening stage, the FebriDx test can assist health professionals with decision-making and may thereby help:

  • identify those patients that should undergo further pathogen-specific testing (e.g. Coronavirus, Flu A/B) when the FebriDx result is positive for viral infection
  • limit unnecessary antibiotic prescriptions that lead to antibiotic resistance when the FebriDx result is negative for bacterial infection

How it works

FebriDx is an easy-to-use, all-in-one, disposable test that enables clinicians to take a fingerstick blood sample and get a rapid result, all within one hand-held device. The test simultaneously detects Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from peripheral whole blood. MxA is an intracellular protein that becomes elevated in the presence of acute viral infection and CRP is an acute-phase inflammatory protein that is elevated in the presence of clinically significant infection.

Supported by science

Clinical performance from two prospective multi-center US clinical trials demonstrate the FebriDx test’s high accuracy and 97-99% negative predictive value to exclude a bacterial infection.1,2

In a United Kingdom outcome study, FebriDx was shown to alter clinical management decisions in 48% of patients tested and reduced unnecessary antibiotic prescriptions by 80%3.

References

  1. Shapiro, N.I., Self, W.H., Rosen, J., Sharp, S.C., Filbin, M.R., Hou, P.C., Parekh, A.D., Kurz, M.C. and Sambursky, R. ‘A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever’, Annals of Medicine, 18 May 2018. https://doi.org/10.1080/07853890.2018.1474002
  2. Self, W.H., Rosen, J., Sharp S.C., Filbin, M.R., Hou, P.C. et al. ‘Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections’, Clin. Med. vol 6, iss. 94, 2017. https://doi.org/10.3390/jcm6100094
  3. Davidson, M. ‘FebriDx point-of-care testing to guide antibiotic therapy for acute respiratory tract infection in UK primary care: a retrospective outcome analysis’, Journal of Infectious Diseases & Preventative Medicine, vol. 5, issue 3, 24 Aug 2017. https://doi.org/10.4172/2329-8731.1000165

Further information

For more information about FebriDx, please visit the FebriDx website.